

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
WO 01/48183 A2

- (51) International Patent Classification<sup>7</sup>: C12N 15/00 (74) Agent: BAYLISS, Geoffrey, Cyril; Boulton Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).
- (21) International Application Number: PCT/EP00/13149
- (22) International Filing Date: 22 December 2000 (22.12.2000) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 9930691.2 24 December 1999 (24.12.1999) GB (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): PLAETINCK, Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). MORTIER, Katherine [BE/BE]; Paddenhoek 20, B-9830 St.-Martens Latem (BE). LISSENS, Ann [BE/BE]; Tiensesteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).
- Published:  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/48183 A2

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

BEST AVAILABLE COPY

BI

18

THIS PAGE BLANK (USPTO)

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*.

5 One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence,  
10 corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on  
15 the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provide improved methods of double-stranded RNA inhibition.

Therefore, according to a first aspect of the  
20 present invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence  
25 substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild  
30 type.

*Caenorhabditis elegans* is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes,  
35 preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type genetic background which confers greater sensitivity to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying examples, introduction of double-stranded RNA (abbreviated herein to dsRNA) into a non wild-type strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the phenotypic level as a more pronounced phenotype.

The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing susceptibility of the nematode to RNAi may, for example, affect the stability of dsRNA or the kinetics of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding proteins involved in RNA synthesis, RNA degradation or the regulation of these processes.

In one preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

nucleases, such as RNases. A particularly preferred example is the *nuc-1* strain. This mutant *C. elegans* strain is known per se in the art.

5 In a second preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode  
10 may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

The term "increased gut uptake" as used herein is taken to mean increased uptake of foreign particles  
15 from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

*C. elegans* feeds by taking in liquid containing its food (e.g. bacteria). It then spits out the  
20 liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called pharyngeal pumping. Once the food particles have been  
25 internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which effect the uptake of compounds from the gut lumen to the surrounding tissues. These include the action of  
30 multi-drug resistance proteins, multi-drug resistance related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport of molecules through the gut wall.

*C. elegans* mutants which exhibit increased uptake  
35 of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the C.

*C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "C. elegans: Modern biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, Gent, Belgium under accession number LMBP 5334CB. The phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either *nuc-1* or gun single mutants.

For the avoidance of doubt, where particular characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans*, wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, *Caenorhabditis elegans: Modern biological analysis of an organism*, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode *Caenorhabditis elegans*, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans II*, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.



Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food  
5 organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that variations in the food organism can result in enhanced  
10 *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said  
15 nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a  
20 modification selected to provide increased expression or persistence of the double-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can be any modification which results in increased  
25 expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which have a direct effect on the rate of transcription. In  
30 a preferred embodiment, the food organism is an RNase III minus *E. coli* strain, or any other RNase negative strain.

According to a still further aspect of the invention there is provided a method of inhibiting  
35 expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

5 In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing  
10 double-stranded RNA structures following ingestion into a nematode.

In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that  
15 they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

Several different arrangements of promoters may  
20 be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical. Transcription from the opposable promoters produces  
25 two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate  
30 sequence, corresponding to a region of a target gene. pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans unc-22* gene. In an alternative arrangement, DNA fragments corresponding to a region of the target gene may be  
35 placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the sense/antisense fragments are co-transcribed to

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics. Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire in *Methods in Cell Biology*, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance with the method of the invention can be achieved using a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode, resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for inhibition.

It is preferred to use dsRNA comprising a nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor variations such as insertions, deletions and single base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as used herein is to be interpreted accordingly. Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence identity. Sequence identity may be conveniently calculated based on an optimal alignment, for example using the BLAST program accessible at [WWW.ncbi.nlm.nih.gov](http://WWW.ncbi.nlm.nih.gov).

The invention will be further understood with reference to the following non-limiting Examples, together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

5 Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans unc-22* gene cloned in pGN1).

10 Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

15 Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc).

20 Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

25 Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

30 Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

35 Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

plasmid pGX22.

5 Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGX52.

10 Figure 11 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

15 Figure 12 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGX104

20

**Example 1**

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

**5 Introduction**

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA. The possibility of DNA delivery and dsRNA delivery has  
10 previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

For this experiment the following *E. coli* strains were  
15 used:

1. MC1061: F-*araD139*  $\Delta$ (*ara-leu*)7696 *galE15 galK16*  $\Delta$ (*lac*)X74 *rpsL* (*Str<sup>r</sup>*) *hsdR2* (*r<sub>k</sub><sup>-</sup> m<sub>k</sub><sup>+</sup>*) *mcrA mcrB1*  
- regular host for various plasmids,  
20 - Wertman et al., (1986) Gene 49:253-262,  
- Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.
- 25 2. B21(DE3): F- *ompT(lon)* *hsdS<sub>B</sub>* (*r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>*; an *E. coli* B strain) with DE3, a  $\lambda$  prophage carrying the T7 RNA polymerase gene.  
- regular host for IPTG inducible T7 polymerase  
30 expression,  
- Studier et al. (1990) Meth. Enzymol. 185:60-89
3. HT115 (DE3): F- *mcrA mcrB* IN(*rrnD-rrnE*) 1  $\lambda$ -*rnc14::tr10* (DE3 lysogen: *lacUV5*  
35 promoter-T7polymerase)  
- host for IPTG inducible T7 polymerase

expression,

- RNaseIII-,

- Fire A, Carnegie Institution, Baltimore, MD,  
Pers. Comm.

5

For this experiment the following *C. elegans* strains  
were used:

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans* *nuc-1*(el393): *C. elegans* strain with a  
reduced endonuclease activity (>95%); condensed  
chromatin persists after programmed cell death;  
ingested (bacterial) DNA in the intestinal lumen  
is not degraded. Several alleles are described:  
el392 (strong allele: has been used for the  
experiments described below); n887 (resembles  
el392) and n334 (weaker allele)  
- Stanfield et al. (1998) East Coast Worm  
meeting abstract 171,  
- Anonymous, Worm Breeder's Gazette 1(1):17b  
Hevelone et al. (1988) Biochem. Genet. 26:447-461  
- Ellis et al., Worm breeder's Gazette 7(2):44  
- Babu, Worm Breeder's gazette 1(2):10  
- Driscoll, (1996) Brain Pathol. 6:411-425  
- Ellis et al., (1991) Genetics 129:79-94

For this experiment the following plasmids were used:

- pGN1: A vector encoding for ampicillin resistance,  
harbouring a multiple cloning site between two  
convergent T7 promoters.
- pGN8: pGN1 containing a genomic fragment of *unc-22*.  
Decreased *unc-22* expression via RNAi results in a  
"twitching" phenotype in *C. elegans*.



**Experimental conditions**

12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M CaCl<sub>2</sub>, 9.5 ml 0.1 ml MgSO<sub>4</sub>, 25 ml 1M KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub> buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH<sub>3</sub>COONH<sub>4</sub> 7.5 M).

10

The dried plates were spotted with approximately 50 µl of an overnight culture of bacteria. When IPTG induction was required, 50 µl of a 10 mM stock solution of IPTG was dropped on top of the bacteria lawn, and incubated at 37°C for approximately 4 hours. Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of the seeded nematodes were tested for the twitching phenotype.

15

20

**Results**

Table 1: Percentage of the offspring that show the twitching phenotype

5	<b>MC1061</b>	<b>N2</b>	<b><i>nuc-1</i></b>
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	0%	0%
	pGN8 + IPTG	0%	0%
10	<b>BL21 (DE3)</b>		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	20% (+)	>90% (++)
	pGN8 + IPTG	20% (+)	>90% (++±)
15	<b>HT115 (DE3)</b>		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	50% (±)	>90% (++)
20	pGN8 + IPTG	80% (++)	>90% (+++)

20 %: percentage twitchers

+: weak twitching

++: twitching

+++: strong twitching

25

**Conclusions**

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment.

30

Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the *unc-22* fragment cloned in pGN8 is not

expressed as dsRNA.

5 The experiment with *E. coli* strain BL21(DE3) and  
nematode strain N2 shows expected results. BL21(DE3)  
harbouring plasmid pGN1 does not result in any  
twitching as the pGN1 vector is an empty vector. BL21  
(DE3) harbouring PGN8 results in the expression of  
unc-22 dsRNA. When this dsRNA is fed to the N2  
nematode (indirectly by feeding with the bacteria that  
10 produce the dsRNA), this results in a twitching  
phenotype, indicating that the dsRNA is able to pass  
the gut barrier and is able to perform its interfering  
activity.

15 Surprisingly the RNAi effect of the unc-22 dsRNA was  
even more pronounced in *C. elegans* strain *nuc-1* than  
in the wild type N2 strain. Although one may expect  
that the *nuc-1* mutation results in the non-degradation  
or at least in a slower degradation of DNA, as the  
20 NUC-1 protein is known to be involved in DNase  
activity, we clearly observe an enhancement of the  
RNAi induced phenotype in *C. elegans* with a *nuc-1*  
background. The *nuc-1* mutation has not been cloned  
yet, but it has been described that the gene is  
25 involved in nuclease activity, and more particularly  
DNase activity. If the NUC-1 protein is a nuclease, it  
may also have activity on nuclease activity on dsRNA,  
which would explain the enhanced RNAi phenotype. The  
*nuc-1* gene product may be a nuclease, or a regulator  
30 of nuclease activity. As the mode of action of RNAi is  
still not understood, it is also possible that the  
NUC-1 protein is interfering in the mode of action of  
RNAi. This would explain why a *nuc-1* mutant is more  
sensitive to RNAi.

35

The experiment with the *E. coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain. The RNA interference observed with the *unc-22* dsRNA is even higher. In comparison with strain BL21(DE3) this could be expected, as HT115(DE3) is a RNase III minus strain, and hence is expected to produce larger amounts of dsRNA, resulting in more prominent RNAi. This indicates further that the RNAi observed in this experiment is the result of the dsRNA produced by the bacteria fed to the *C. elegans*. Feeding *C. elegans* *nuc-1* with HT115(DE3) harbouring pGN8 also results in higher RNA interference phenotype than feeding the same bacteria to *C. elegans* wild-type strain N2. Once again this indicates that improved RNAi can be realised using a nuclease negative *C. elegans* and more particularly with a with the *C. elegans nuc-1* (e1392) strain.

#### Summary

RNA interference can be achieved in *C. elegans* by feeding the worms with bacteria that produce dsRNA. The efficiency of this RNA interference is dependent both on the *E. coli* strain and on the genetic background of the *C. elegans* strain. The higher the level of dsRNA production in the *E. coli*, the more RNAi is observed. This can be realised by using efficient RNA expression systems such as T7 RNA polymerase and RNAase negative strains, such as RNaseIII minus strains. In this example the level of dsRNA production varied: HT115(DE3)>BL21(DE3)>MC1061.

RNA interference is high in *C. elegans* strains that are nuclease negative, or that are influenced in their nuclease activity. This can be realised by using a mutant strain such as *C. elegans nuc-1*. In this example the sensitivity to RNAi varied: *C. elegans nuc-1* >> *C. elegans* N2

**Example 2**

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake (designated herein 'gun' mutants). Strains bg77, bg78, bg83, bg84, bg85, bg86, bg87, bg88 and bg89 are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

**Experimental conditions:**

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100µg/ml) and 5 ml of 100mM stock IPTG) per well
- the dried plates were spotted with 25µl of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- individual nematodes at the L4 growth stage were then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- the adult F1 offspring of the seeded nematodes were tested for the twitching phenotype

**Results:**

Table 2:

	20°C/6d	pGN1 HT115DE3	pGN8 BL2DE3	pGN8 HT115DE3	
5	N2	0	1	1	
	<i>nuc-1</i>	0	1-2	3	
	bg77	0	1-2	3	
	bg78	0	1	1-2	
	bg83	0	1	1	
10	bg84	0	1-2	3	
	bg85	0	1	2-3	
	bg86	0	1	2-3	
	bg87	0	1	1	
	bg88	0	1	1	
15	bg89	0	1	1	

figure legend:

- 0 = no twitching
- 1 = no to weak phenotype
- 2 = clear phenotype
- 3 = strong phenotype

**Conclusions**

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1* *C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains bg77, bg84, bg85, bg86 show improved sensitivity to RNAi compared to Wild-type.

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

5 Double mutants were constructed to test the prediction  
that gun/nuc mutants would even show more enhanced  
RNAi sensitivity. As an example, the crossing  
strategy with gun strain bg85 is shown, similar  
crosses can be conducted with other gun strains, such  
10 as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

15 F1 cross: nuc-1 x gun(bg85)/+ males

F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)  
nuc-1 x +/+; nuc-1/0 males (50%)

20 F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)  
+/+; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th  
plate high staining with BCECF)

25 F5 retest: gun(bg85); nuc-1 (100% progeny of F4  
singled high staining with BCECF)

To select for the gun phenotype, the fluorescence  
precursor BCECF-AM is used (obtainable from Molecular  
30 probes). The precursor BCECF-AM is cleaved by  
esterases present in the gut of the worm to generate  
the dye BCECF which is fluorescent at pH values above  
6. This allows selection for worms that have a gun  
phenotype. BCECF-AM is taken up through the pharynx  
35 into the gut lumen and is not fluorescent until it has  
been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

5     **Example 3**

Improved RNAi feeding in liquid culture using *nuc-1*(el393) *C. elegans*.

**Introduction**

10    N2 and *nuc-1* *C.elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using  
15    the *nuc-1* strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E.coli* strains were used:

20

1.    HT115 (DE3): F- *mcrA mcrb* IN(rrnD-rrnE) 1  $\lambda$ -  
      *rnc14::tr10* (DE3 lysogen: lacUV5 promoter -T7 polymerase)  
      - host for IPTG inducible T7 polymerase expression  
25    - RNaseIII<sup>-</sup>  
      - Fire A, Carnegie Institution, Baltimore, MD, Pers. Comm.

For this experiment, following *C. elegans* strains were used:

30

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans nuc-1*(el393): *C. elegans* strain with a  
35    reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;



ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described:

- 5 e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
- Stanfield et al. (1998) East Coast Worm meeting abstract 171
  - Anonymous, Worm Breeder's Gazette 1(1):17b
  - Hevelone et al. (1988) Biochem. Genet. 26:447-461
  - 10 - Ellis et al., Worm breeder's Gazette 7(2):44
  - Babu, Worm Breeder's gazette 1(2):10
  - Driscoll, (1996) Brain Pathol. 6:411-425
  - Ellis et al., (1991) Genetics 129:79-94

15

For this experiment, the following plasmids that all give lethal phenotypes in *C. elegans* via RNAi were used:

- 20 pGX22: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid C04H5.6 corresponding to a member of the RNA helicase family.

- pGX52: a vector encoding ampicillin resistance,  
25 containing a genomic fragment of cosmid K11D9.2b corresponding to sarco/endoplasmic  $\text{Ca}^{2+}$  ATPase also known as SERCA.

- pGZ18: a vector encoding ampicillin resistance,  
30 containing a genomic fragment of cosmid T25G3.2 corresponding to a chitin like synthase gene.

- pGX104: a vector encoding ampicillin resistance,  
containing a genomic fragment of cosmid Y57G11C.15  
35 corresponding to sec-61, a transport protein.

**Experimental conditions**

- 5       - 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 10       - 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 15       - 3 nematodes at the L1 growth stage of N2 and nuc-1 strain were then placed in single wells, 3 L1's per well. Per experimental set up, 16 wells were used (n=16).
- 20       - the plates were incubated at 25°C for 5 days to allow offspring to be formed.
- the plates were visually checked and the following phenotypes could be scored per individual well:
- 25       **no effect:** L1's developed to adults and gave normal offspring.
- no F1 offspring:** L1's developed to adults and gave no offspring.
- 30       **acute lethal:** original L1 did not mature and died.

**Results**

- 35       The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

a percentage of the total (n=16) on the y-axis for both N2 and nuc-1 strains.

### Conclusions

- 5 The following genes were tested in this liquid RNAi assay:
- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
  - 10 - SERCA: a sarco/endoplasmic  $\text{Ca}^{2+}$  ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
  - 15 - T25G3.2: a chitin like synthase gene. RNAi of this gene causes dead eggs.
  - sec-61: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
  - 20 - RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the nuc-1 *C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and Sec-61 the difference between the N2 wild-type strain and the nuc-1 strain is less pronounced.

**Example 4****Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi**

A set of primers for each gene was designed on the basis of sequence data available in the publicly accessible *C. elegans* sequence database (Acedb).

The cosmid names relate to:

1. **C04H5.6**=member of RNA helicase
2. **K11D9.2b**=SERCA
3. **Y57G11C.15**=transport protein sec-61
4. **T25G3.2**=chitin synthase like

The following primer sequences were designed:

1. **C04H5.6F** 5'-TGCTCAGAGAGTTTCTCAACGAACC-3'  
**C04H5.6R** 5'-CAATGTTAGTTGCTAGGACCACCTG-3'
2. **K11D9.2bF** 5'-CAGCCGATCTCCGTCTTGTG-3'  
**K11D9.2bR** 5'-CCGAGGGCAAGACAACGAAG-3'
3. **Y57G11C.15F** 5'-ACCGTGGTACTCTTATGGAGCTCG-3'  
**Y57G11C.15R** 5'-TGCAGTGGATTGGGTCTTCG-3'
4. **T25G3.2F**  
5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'  
**T25G3.2R**  
5'-GGGGACCACTTTGTACAAGAAAGCTGGGTGGAGAAGCATTCGAGAGTTTG-3'

PCR was performed on genomic DNA of N2 strain *C. elegans* to give PCR products of the following sizes:

- 1326bp for C04H5.6
- 1213bp for K11D9.2b

1024bp for Y57G11C.15

1115bp for T25G3.2

5 The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15  
were linked to *Bst*XI adaptors (Invitrogen) and then  
cloned into the pGN29 vector cut with *Bst*XI. pGN29  
contains two T7 promoters and two T7 terminators  
flanking a cloning site which is adapted for  
facilitated cloning of PCR fragments, comprising a  
10 stuffer DNA flanked by two *Bst*XI sites (see schematic  
Figure 3). The resulting plasmids were designated  
pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104  
(Y57G11C.15).

15 The PCR fragment of T25G3.2 was cloned into pGN39 via  
recombination sites based on the GATEWAY™ cloning  
system (Life Technologies, Inc). pGN39 contains two  
T7 promoters and two T7 terminators flanking a cloning  
site which facilitates "High Throughput" cloning based  
20 on homologous recombination rather than restriction  
enzyme digestion and ligation. As shown schematically  
in Figure 4, the cloning site comprises *att*R1 and  
*att*R2 recombination sites from bacteriophage lambda  
flanking a gene which is lethal to *E. coli*, in this  
25 case the *ccdB* gene. This cloning site is derived from  
the Gateway™ cloning system commercially available  
from Life Technologies, Inc. The Gateway™ cloning  
system has been extensively described by Hartley et  
al. in WO 96/40724 (PCT/US96/10082).

30

**Example 5**

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

5

The screen was performed in *unc-31*(e928) mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethylester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

15

Mutagenesis

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

Day 2: P0 was divided over several large agar plates

Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's layed were checked every hour and de F1's were removed when 10-20 eggs per F1 were counted

Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

30

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x) 9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

35

Table 3: Isolation of mutations for increased staining with BCECF-AM

	Total P0	Total F1	Total F2	screened chromosomes	number of strains isolated
5	(counted)	(estimated)	(calculated)	(estimated)	(counted)
	2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

- 10 1. backcrossing *unc-31; gun* --> *unc-31; gun*
  - *unc-31; gun* x WT males
  - singled 2x5 WT hermaphrodites F1s (*unc-31/+;gun/+*)
  - singled 50 WT hermaphrodites F2s (1/4 homozygous)
  - select strains segregating 1/4 *unc*
- 15 - stain *unc* strains with BCECF-AM
  - from positive strains pick *unc* homozygous
  - retest 100 % *unc* strains with BCECF-AM
  - kept 1 strain (backcrossed)
- 20 2. *unc-31* background was crossed out-->+; *gun*
  - *unc-31; gun* x WT males
  - singled 2x5 WT hermaphrodites F1s (*unc-31/+;gun/+*)
  - singled 50 WT hermaphrodites F2s (1/4 homozygous)
  - select strains which did not segregate *unc* F3s
- 25 anymore
  - stain non *unc* strains with BCECF-AM
  - 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)
- 30 3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
  - *gun* x WT males
  - WT hermaphrodites x F1 males (*gun/+*)
  - singled 10 WT hermaphrodites F2s (1/2 heterozygous)
- 35 - singled 50 WT hermaphrodites F3s (1/8 homozygous)

- 31 -

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1*(X)  
 5 mutant--> *gun; nuc-1*  
 - *gun* x WT males  
 - *nuc-1* x *gun/+* males  
 - *nuc-1* x *gun/+; nuc-1/0* or *+/+; nuc-1/0* males  
 - singled 10 WT hermaphrodite progeny (*nuc-1*  
 10 homozygous,  $\frac{1}{2}$  heterozygous *gun*)  
 - singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)  
 - stain strains with BCECF-AM  
 - retested positives with BCECF-AM and finally 1 was  
 15 selected and kept

Table 6: Strains derived from *gun* mutations

	<i>gun</i>		<i>unc-31; gun</i>		<i>unc-31; gun</i>			<i>gun; nuc-1</i>	
	original isolate		backcrossed (1x)		outcrossed (1x)		3x b.c.	from 3x b.c.	
	allele number	isolation number	strain number	isolation number	strain number	isolation number	strain number	strain number	strain number
20	bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674	UG 777
25	bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675	-
	bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676	-
	bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677	UG 774
	bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717		UG 775
	bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678	UG 776
30	bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679	-
	bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680	-
	bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671	-



SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

5 SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

SEQ ID NO: 4 complete sequence of pGN39

10 SEQ ID NO: 5 complete sequence of pGX22

SEQ ID NO: 6 complete sequence of pGX52

15 SEQ ID NO: 7 complete sequence of pGX104

SEQ ID NO: 8 complete sequence of pGZ8

SEQ ID NO: 9 primer C04H5.6F

20 SEQ ID NO: 10 primer C04H5.6R

SEQ ID NO: 11 primer K11D9.2bF

25 SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

SEQ ID NO: 14 primer Y57G11C.15R

30 SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to  
5 said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode  
10 has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.
2. A method as claimed in claim 1 wherein the  
15 nematode is a microscopic nematode.
3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.
- 20 4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.
5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic  
25 background.
6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild  
30 type.
7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain *nuc-1*.
- 35 8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

5

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type.

10

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

15

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

20

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

25

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

30

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

35

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

5

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

10

18. A method as claimed in claim 26 wherein the two promoters are identical.

15

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

25

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

30

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

35

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

24. A method as claimed in claim 23 wherein the food organism is a bacterium.

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNase III minus strain or any other RNase negative strain.

27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28  
to 31 wherein the nematode has a mutant genetic  
5 background.

33. A method as claimed in claim 32 wherein the  
nematode is mutant *C. elegans* strain bg85.

10 34. A method as claimed in any one of claims 28  
to 33 wherein the DNA capable of producing a double-  
stranded RNA structure is a vector comprising a  
promoter or promoters orientated relative to a DNA  
sequence such that they are capable of initiating  
15 transcription of said DNA sequence to RNA capable of  
forming a double-stranded structure upon binding of an  
appropriate RNA polymerase to said promoter or  
promoters.

20 35. A method as claimed in claim 34 wherein the  
vector comprises two promoters flanking the DNA  
sequence.

25 36. A method as claimed in claim 35 wherein the  
two promoters are identical.

30 37. A method as claimed in claim 34 wherein the  
vector comprises a single promoter and further  
comprises said DNA sequence in a sense and an  
antisense orientation relative to said promoter.

35 38. A method as claimed in any one of claims 34  
to 37 wherein the nematode is adapted to express an  
RNA polymerase capable of initiating transcription  
from said promoter or promoters.

39. A method as claimed in any one of claims 34

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.


*FIG. 1.*



FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.




FIG. 7.




FIG. 8.




FIG. 9.




FIG. 10.






FIG. 11.





FIG. 12.



1  
SEQUENCE LISTING

&lt;110&gt; DEVGEN NV

&lt;120&gt; IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

&lt;130&gt; SCB/53711/001

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 14

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 3216

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGN1

&lt;400&gt; 1

gagtgcacca	tatgcggtgt	gaaataccgc	acagatgcgt	aaggagaaaa	taccgcatca	60
ggcgaaattg	taaacgttaa	tattttgtta	aaattcgcgt	taaatatttg	ttaaatcagc	120
tcatttttta	accaataggc	cgaaatcggc	aaaatccctt	ataaatcaaa	agaatagacc	180
gagatagggt	tgagtgttgt	tccagtttgg	aacaagagtc	cactattaaa	gaacgtggac	240
tccaacgtca	aagggcgaaa	aaccgtctat	cagggcgatg	gccactacg	tgaaccatca	300
cccaaatcaa	gttttttgcg	gtcgaggtgc	cgtaaagctc	taaatcggaa	ccctaaaggg	360
agcccccgat	ttagagcttg	acggggaaaag	ccggcgaaacg	tggcgagaaa	ggaaggggaag	420
aaagcgaaaag	gagcggggcgc	tagggcgctg	gcaagtgtag	cggtcacgct	gcgcgtaacc	480
accacacccg	ccgcgcttaa	tgcgccgcta	cagggcgcgct	ccattcgcca	ttcaggctgc	540
gcaactgttg	ggaagggcga	tcggtgcggg	cctcttcgct	attacgccag	ctggcgaaaag	600
ggggatgtgc	tgcaaggcga	ttaagttggg	taacgccagg	gttttcccag	tcacgacgtt	660
gtaaaacgac	ggccagtga	ttgtaatacg	actcactata	gggcgaattc	gagctcggtg	720
cccggggatc	ctctagagtc	gaaagcttct	cgccctatag	tgagtcgtat	tacagcttga	780
gtattctata	gtgtcaccta	aatagcttgg	cgtaatcatg	gtcatagctg	tttctgtgtg	840
gaaattgtta	tccgctcaca	attccacaca	acatacgagc	cggaagcata	aagtgtaaag	900
cctgggggtgc	ctaattgagtg	agctaactca	cattaattgc	gttgcgctca	ctgcccgcct	960
tccagtcggg	aaacctgtcg	tgccagctgc	attaatgaat	cggccaacgc	gcggggagag	1020
gcggtttgcg	tattggggcgc	tcttccgctt	cctcgctcac	tgactcgctg	cgctcggtcg	1080
ttcggtcgcg	gcgagcggtg	tcagctcact	caaaggcggg	aatacgggta	tccacagaat	1140
caggggataa	cgcaggaaaag	aacatgtgag	caaaaggcca	gcaaaaggcc	aggaaccgta	1200
aaaaggccgc	gttgctggcg	tttttcgata	ggctccgccc	ccctgacgag	catcacaaaa	1260
atcgacgctc	aagtcagagg	tggcgaaacc	cgacaggact	ataaagatac	caggcgtttc	1320
cccctggaag	ctccctcgctg	cgctctcctg	ttccgaccct	gccgcttacc	ggatacctgt	1380
ccgcctttct	cccttcggga	agcgtggcgc	tttctcatag	ctcacgctgt	aggtatctca	1440
gttcggtgta	ggtcgttcgc	tccaagctgg	gctgtgtgca	cgaaccccc	gttcagccc	1500
accgctgcgc	cttatccggt	aactatcgctc	ttgagtccaa	cccggtaaga	cacgacttat	1560
cgccactggc	agcagccact	ggtaacagga	ttagcagagc	gaggtatgta	ggcgggtgta	1620
cagagttctt	gaagtgtgtg	cctaactacg	gctacactag	aaggacagta	tttggtatct	1680
gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	tagctcttga	tccggcaaac	1740
aaaccaccgc	tggtagcggg	ggtttttttg	tttgcaggca	gcagattacg	cgcagaaaaa	1800
aaggatctca	agaagatcct	ttgatctttt	ctacgggggc	tgacgctcag	tggaaacgaa	1860
actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	gatcttcacc	tagatccttt	1920
taaattaaaa	atgaagtttt	aaatcaatct	aaagtatata	tgagtaaact	tggtctgaca	1980

gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctatatt	cgttcatcca	2040
tagttgcctg	actccccgtc	gtgtagataa	ctacgatacg	ggagggctta	ccatctggcc	2100
ccagtgtcgc	aatgataccg	cgagaccac	gctcaccggc	tccagattta	tcagcaataa	2160
accagccagc	cggaagggcc	gagcgcagaa	gtggtcctgc	aactttatcc	gcctccatcc	2220
agtctattaa	ttgttgccgg	gaagctagag	taagtagttc	gccagttaat	agtttgcgca	2280
acgttggttg	cattgctaca	ggcatcgttg	tgtcacgctc	gtcgtttggt	atggcttcat	2340
tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgttg	tgcaaaaaag	2400
cggtagcttc	cttcggtcct	ccgatcgttg	tcagaagtaa	gttggccgca	gtgttatcac	2460
tcatggttat	ggcagcactg	cataattctc	ttactgtcat	gccatccgta	agatgctttt	2520
ctgtgactgg	tgagtactca	accaagtcac	tctgagaata	ccgcgcccgg	cgaccgagtt	2580
gctcttgccc	ggcgtcaata	cgggataata	gtgtatgaca	tagcagaact	ttaaaagtgc	2640
tcattcattg	aaaacgttct	tcggggcgaa	aactctcaag	gatcttaccg	ctgttgagat	2700
ccagttcgat	gtaacccact	cgtgcaccca	actgatcttc	agcatctttt	actttcacca	2760
gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatgccgc	aaaaaaggga	ataagggcga	2820
cacggaaaatg	ttgaatactc	atactcttcc	tttttcaata	ttattgaagc	atttatcagg	2880
gttattgtct	catgagcggg	tacatatttg	aatgtattta	gaaaaataaa	caaatagggg	2940
ttccgcgcac	atttccccga	aaagtgccac	ctgacgtcta	agaaaccatt	attatcatga	3000
cattaacctt	taaaaatagg	cgtatcacgc	ggccctttcg	tctcgcgcgt	ttcgggtgatg	3060
acggtgaaaa	cctctgacac	atgcagctcc	cggagacggg	cacagcttgt	ctgtaagcgg	3120
atgccgggag	cgacaagcc	cgtcagggcg	gtgcagcggg	tgttggcggg	tgtcggggct	3180
ggcttaacta	tgcggcatca	gagcagattg	tactga			3216

&lt;210&gt; 2

&lt;211&gt; 4620

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGN8

&lt;400&gt; 2

gatccgaatc	tccatgtctg	ttaacagcct	tgacacggaa	tttatattca	tgcccttgag	60
tcaaatcgtc	aacgtggaag	ttggtatcct	tgtctctctc	gcaagcagtc	catctgccag	120
tggcagcatc	ttgcttttca	atgacatagt	gactgatttc	agctcctcca	tcattctctg	180
gttccttcca	tgcaagatca	catccatcct	tgacaatatt	agtacatcg	agaggtccac	240
gtgggcttga	tggatgatca	agaacagtaa	ccttcacttc	agcagtgtca	gttcattct	300
cgttctctgc	cttgatgata	taggttctctg	tatccgaacg	caaagctctc	ttcacatgga	360
atttagtctt	gccgtcttca	ttgttcaact	tcatacgatc	atcagattcg	actggtgttc	420
cttcgaaagt	ccaagtaatt	gttggaattg	gttcaccact	gactggaatg	ttcaatgaga	480
agtcttgtcc	agccttgacc	ttgatttctt	gaatcgagtt	acgatcgatg	actggtggaa	540
ctataattta	attcaatgat	tattagtaat	tgatttagac	tcttaccatt	tctagccttt	600
gcaacagctg	atgctgaatc	agatggatct	cccaatcctg	ccttgttctt	ggcacggatt	660
ctgaattcgt	actttgatcc	ttccttgaga	tttccaacag	tagcattcgt	ttgtccagct	720
ggaacatgag	caacgtcatt	ccagaatggc	gagaactcgt	ccttcatctc	aacaacgtat	780
tcctcgattg	gagcaccacc	gtcgtttgct	ggtggcttcc	attcaaggtc	aacatgatcc	840
ttatcccaat	cagtaatttc	aggagcattt	gtctttcctg	gcttgtcaaa	tggatctttg	900
gcaagtgtgg	ttccgaaggt	ctccaatgga	tcggactctc	cttcagcatt	gacggcagcg	960
acacggaact	gaaaatcaaa	atgttgtagg	caattgagtt	caagattaaa	aaattctcac	1020
tttatattca	tgtccaggaa	taagaccgtc	aacaacagct	gtagtcttat	ctccagcgac	1080
ctttgcagct	ggaaccatc	ttccacttgc	agtatcgtag	ttttcgatca	catagttttc	1140
aattggaata	cctccatcat	catctggtgc	acgccaatc	aaagtacat	gatcaccatg	1200
aacatcgga	acatctaag	gaccatttgg	agaagttggc	ttgtctgaaa	atttaaaata	1260
taaccaaaat	aattgaagaa	aactaatgct	caccaataac	attgatctta	acagttgctt	1320
catcttctcc	atttgattg	acagctttga	tagtgaaagt	tccactgtct	ccacgttcca	1380
tttgcttca	aaccagcttt	gattggtatt	ctgggttatt	aagcttctcg	ccctatagtg	1440
agtcgtatta	cagcttgagt	attctatagt	gtcacctaaa	tagcttggcg	taatcatggt	1500
catagctgtt	tcctgtgtga	aattgttatc	cgctcacaat	tccacacaac	atagcagccg	1560
gaagcataaa	gtgtaaagcc	tggggtgcct	aatgagttag	ctaactcaca	ttaattgcgt	1620

tgcgctcact	gcccgcctttc	cagtcgggaa	acctgtcgtg	ccagctgcat	taatgaatcg	1680
gccaacgcgc	ggggagaggc	ggtttgcgta	ttgggcgctc	ttccgcttcc	tcgctcactg	1740
actcgctgcg	ctcggtcggt	cggctgcggc	gagcgggtatc	agctcactca	aaggcggtaa	1800
tacggttatc	cacagaatca	ggggataacg	caggaaagaa	catgtgagca	aaaggccagc	1860
aaaaggccag	gaaccgtaaa	aaggccgcgt	tgctggcggtt	tttcgatagg	ctccgcccc	1920
ctgacgagca	tcacaaaaat	cgacgctcaa	gtcagagggtg	gcgaaacccg	acaggactat	1980
aaagatacca	ggcgctttccc	cctggaagct	ccctcgtgcg	ctctcctggt	ccgaccctgc	2040
cgcttaccgg	atacctgtcc	gcctttctcc	cttcgggaag	cgtaggcgctt	tctcatagct	2100
cacgctgtag	gtatctcagt	tcgggtgtagg	tcgttcgctc	caagctgggc	tgtgtgcacg	2160
aaccccccg	tcagcccgac	cgctgcgcct	tatccggtaa	ctatcgtctt	gagtccaacc	2220
cggtaaagaca	cgacttatcg	ccactggcag	cagccactgg	taacaggatt	agcagagcga	2280
ggtatgtagg	cggtgctaca	gagttcctga	agtgggtggc	taactacggc	tacactagaa	2340
ggacagtatt	tggtagctgc	gctctgctga	agccagttac	cttcggaaaa	agagttggta	2400
gctcttgatc	cggcaaaaca	accaccgctg	gtagcgggtg	tttttttgtt	tgcaagcagc	2460
agattacgcg	cagaaaaaaa	ggatctcaag	aagatccttt	gatcttttct	acggggtctg	2520
acgctcagtg	gaacgaaaaa	tcacgttaag	ggattttggg	catgagatta	tcaaaaagga	2580
tcttcaccta	gattcctttta	aattaaaaat	gaagttttta	atcaatctaa	agtatatatg	2640
agtaaaacttg	gtctgacagt	taccaatgct	taatcagtga	ggcacctatc	tcagcgatct	2700
gtctattttcg	ttcatccata	gttgccctgac	tccccgtcgt	gtagataact	acgatacggg	2760
agggttacc	atctggcccc	agtgtgcaa	tgataccgcg	agaccacgc	tcaccggctc	2820
cagatttatc	agcaataaac	cagccagccg	gaagggccga	gcgcagaagt	ggtcctgcaa	2880
ctttatccgc	ctccatccag	tctattaatt	gttgccggga	agctagagta	agtagttcgc	2940
cagttaatag	tttgcgcaac	gttggttgca	ttgctacagg	catcgtgggtg	tcacgctcgt	3000
cgtttggtat	ggcttcattc	agctccggtt	cccaacgac	aaggcgagtt	acatgatccc	3060
ccatgttgtg	caaaaaagcg	gttagctcct	tcggctctcc	gatcgttgtc	agaagtaagt	3120
tggccgcagt	gttatcactc	atggttatgg	cagcactgca	taattctctt	actgtcatgc	3180
catccgtaag	atgcttttct	gtgactgggtg	agtactcaac	caagtcattc	tgagaataacc	3240
gcgcccggcg	accgagttgc	tcttgcccgg	cgtcaatacg	ggataatagt	gtatgacata	3300
gcagaacttt	aaaagtgtc	atcattggaa	aacgttcttc	ggggcgaaaa	ctctcaagga	3360
tcttaccgct	gttgagatcc	agttcgatgt	aaccactcg	tgacccaac	tgatcttcag	3420
catcttttac	tttcaccagc	gtttctgggt	gagcaaaaac	aggaaggcaa	aatgccgcaa	3480
aaaagggaat	aagggcgaca	cggaaatggt	gaataactcat	actcttcctt	tttcaatatt	3540
attgaagcat	ttatcagggt	tattgtctca	tgagcggata	catatttgaa	tgtatttaga	3600
aaaataaaca	aataggggtt	ccgcgcacat	ttccccgaaa	agtgccacct	gacgtctaag	3660
aaaccattat	tatcatgaca	ttaacctata	aaaataggcg	tatcacgagg	ccctttcgtc	3720
tcgcgcggtt	cggtgatgac	ggtgaaaacc	tctgacacat	gcagctcccg	gagacgggtca	3780
cagcttgctc	gtaagcggat	gccgggagca	gacaagcccg	tcagggcgcg	tcagcgggtg	3840
ttggcgggtg	tcggggctgg	cttaactatg	cggcatcaga	gcagattgta	ctgagagtgc	3900
accatatgcg	gtgtgaaata	ccgcacagat	gcgtaaggag	aaaataccgc	atcaggcgaa	3960
attgtaaacg	ttaatatatt	gttaaaattc	gcgttaaata	tttggttaaat	cagctcattt	4020
tttaaccaat	aggccgaaat	cggcaaaatc	ccttataaat	caaaagaata	gaccgagata	4080
gggttgagtg	ttgttccagt	ttggaacaag	agtccactat	taaagaacgt	ggactccaac	4140
gtcaaagggc	gaaaaaccgt	ctatcagggc	gatggcccac	tacgtgaacc	atcacccaaa	4200
tcaagttttt	tgcggctcag	gtgccgtaaa	gctctaaatc	ggaaccctaa	agggagcccc	4260
cgatttagag	cttgacgggg	aaagccggcg	aacgtggcga	gaaaggaagg	gaagaaagcg	4320
aaaggagcgg	gcgctagggc	gctggcaagt	gtagcgggtc	cgctgcgcgt	aaccaccaca	4380
cccgccgcgc	ttaatgcgcc	gctacagggc	gcgtccattc	gccattcagg	ctgcgcaact	4440
gttggaaggg	gcgatcggtg	cgggcctctt	cgctattacg	ccagctggcg	aaagggggat	4500
gtgctgcaag	gcgattaagt	tgggtaacgc	cagggttttc	ccagtcacga	cgttgtaaaa	4560
cgacggccag	tgaattgtaa	tacgactcac	tatagggcga	attcgagctc	ggtacccggg	4620

&lt;210&gt; 3

&lt;211&gt; 4756

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGX22

&lt;400&gt; 3

tgctcagaga	gtttctcaac	gaacccgatt	tggctagtta	taggtaattt	ttagaacatt	60
tacaaaaaca	gcaaaaaaac	caaacattca	ggatttttgt	ttttaattaa	gaaaaaaatc	120
gatcgctctt	aaattttta	caatacttcg	aataaaccca	aaaaaaaacg	aaaaaaaatc	180
ctgtttccag	tgtaatgatg	attgacgagg	ctcacgaacg	tactctacac	acggatattc	240
tattcggttt	agtcaaagat	attgcaagat	tccgaaagga	tttgaagctt	ctcatctctt	300
ctgcaacact	tgacgctgaa	aagttctcca	gtttcttcga	cgacgctccg	attttccgaa	360
ttccgggaacg	cagattcccg	gtggacattt	actatacaca	ggctcccga	gcgactacg	420
tcgacggcgc	tatcgtcaca	attatgcaga	ttcacttgac	ccagccactt	cccggcgata	480
ttttggtatt	tctgactggt	caggaagaaa	tcgaaactgt	acaggaagca	cttatggaa	540
ggtcgaaagc	actgggatcg	aagattaagg	agcttattcc	gctgccggtt	tatgcgaatt	600
tgcccagtg	tttgaggcg	aagattttcg	agccaacgcc	gaaagatgcg	agaaaggtag	660
atttttctta	caaatttttt	ccaaaaaaa	atccgagaaa	aatctacaaa	atttcaggca	720
aaaactgttt	catttttattc	ctaactagtt	ttttagcaaa	cgtttagatt	taacaaaact	780
gaacaaat	gaagttttcc	aattttaaaaa	ataaatgttt	cggaaagttt	attgaaaaat	840
ctgaaattgc	tatcctctcg	tatctgcaaa	aaaaacactt	taaaaaatgc	tctgttcttt	900
gaaaatttct	aaactgaaaa	atttgaaatt	tctgaaaatt	gtgataattt	tataaaattt	960
tatagaaat	gtaagcattc	cagaaaaata	tcaaaaattt	cgagaaaatt	ctgaaaaaat	1020
ccagaaatat	taacagaaaa	aaaatctttt	gaaacatctg	aaaattaaaa	taatttgaat	1080
ttacattttt	ttttttggga	tttccttaaa	atcactatga	atttaccact	aaattttttg	1140
caaaaaatta	ttttttta	ttcaaagaaa	aagcaaagaa	ttttaaaata	tcaaaaagtc	1200
caaatttggt	tcggtgaatt	tttaaaataa	cattttcaag	ataattttta	gttaatcaaa	1260
acattccacg	catttctagt	ttcccaaatt	tctctaaatt	tcaggtggtc	ctagcaacta	1320
acattgccag	cacaatggat	ctcgagggat	cttccatacc	taccagttct	gcgcctgcag	1380
gtcgcggccg	cgactctcta	gacgcgtaag	cttactagca	taaccccttg	gggcctctaa	1440
acgggtcttg	aggggttttt	tgagcttctc	gccctatagt	gagtcgtatt	acagcttgag	1500
tattctatag	tgtcacctaa	atagcttggc	gtaatcatgg	tcatagctgt	ttcctgtgtg	1560
aaattgttat	ccgctcaca	ttccacacaa	catacagagc	ggaagcataa	agtgtaaagc	1620
ctgggtgtgc	taatgagtga	gctaactcac	attaattgcy	ttgcgctcac	tgcccgcttt	1680
ccagtcggga	aacctgtcgt	gccagctgca	ttaatgaatc	ggccaacgcg	cggggagagg	1740
cggtttgcgt	attgggcgct	cttccgcttc	ctcgtcact	gactcgtgc	gctcggtcgt	1800
tcggctgcgg	cgagcgggat	cagctcactc	aaaggcggta	atacggttat	ccacagaatc	1860
aggggataac	gcaggaaaga	acatgtgagc	aaaaggccag	caaaaggcca	ggaaccgtaa	1920
aaaggccgcg	ttgctggcgt	ttttcgatag	gctccgcccc	cctgacgagc	atcacaaaaa	1980
tcgacgtca	agtacagagg	ggcgaaaccc	gacaggacta	taaagatacc	aggcgtttcc	2040
ccctggaagc	tccctcgtgc	gctctcctgt	tccgaccctg	ccgcttaacc	gatacctgtc	2100
cgcccttctc	ccttcgggaa	gcgtggcgct	ttctcatagc	tcacgctgta	ggtatctcag	2160
ttcggctgat	gtcgctcgct	ccaagctggg	ctgtgtgcac	gaaccccccg	ttcagccccg	2220
ccgctgcgcc	ttatccggta	actatcgtct	tgagttcaac	ccggtaaagc	acgacttatc	2280
gccactggca	gcagccactg	gtaacaggat	tagcagagcg	aggatgttag	gcgggtgctac	2340
agagttcttg	aagtgtggc	ctaactacgg	ctacactaga	aggacagtat	ttggtatctg	2400
cgtctgctg	aagccagtta	ccttcggaaa	aagagttggt	agctcttgat	ccggcaaaaa	2460
aaccaccgct	ggtagcggtg	gtttttttgt	ttgcaagcag	cagattacgc	gcagaaaaaa	2520
aggatctcaa	gaagatcctt	tgatcttttc	tacgggggtc	gacgctcagt	ggaacgaaaa	2580
ctcacgttaa	gggatttttg	tcatgagatt	atcaaaaagg	atcttcacct	agatcctttt	2640
aaattaaaaa	tgaagtttta	aatcaatcta	aagtatatat	gagtaaaact	ggtctgacag	2700
ttaccaatgc	ttaatcagtg	aggcacctat	ctcagcgatc	tgtctatttc	gttcatccat	2760
agttgcctga	ctccccgctg	tgtagataac	tacgatacgg	gagggcttac	catctggccc	2820
cagtgtgcga	atgataccgc	gagaccacgc	ctcaccggt	ccagatttat	cagcaataaa	2880
ccagccagcc	ggaagggcg	agcgcagaag	tggtcctgca	actttatccg	cctccatcca	2940
gtctattaat	tgttgccggg	aagctagagt	aagtagttcg	ccagttaata	gtttgcgcaa	3000
cgttggtggc	attgctacag	gcacgtgggt	gtcacgctcg	tcgtttggta	tggttccatt	3060
cagctccggt	tcccaacgat	caaggcgagt	tacatgatcc	cccatgttgt	gcaaaaaagc	3120
ggttagctcc	ttcggtcctc	cgatcgttgt	cagaagtaag	ttggccgcag	tggtatcact	3180
catggttatg	gcagcactgc	ataattctct	tactgtcatg	ccatccgtaa	gatgcttttc	3240
tgtgactggt	gagtactcaa	ccaagtcatt	ctgagaatac	cgcccccggc	gaccgagttg	3300
ctcttgcccc	gcgtcaatac	gggataatag	tgtatgacat	agcagaactt	taaaagtgtc	3360

```

catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc 3420
cagttcgaatg taaccacttc gtgcacccaa ctgatcttca gcatctttta ctttcaccag 3480
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaaggga taaggcgac 3540
acggaaatgt tgaatactca tactcttctt ttttcaatat tattgaagca tttatcaggg 3600
ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggg 3660
tccgcgcaca ttcccccga aagtgccacc tgacgtctaa gaaaccatta ttatcatgac 3720
attaacctat aaaaataggc gtatcacgag gccctttcgt ctgcgcggtt tcggtgatga 3780
cggtgaaaaac ctctgacaca tgcagctccc ggagacgggt acagcttggt tgtaagcgga 3840
tgccgggagc agacaagccc gtcagggcgc gtcagcgggt gttggcgggt gtcggggctg 3900
gcttaactat gcggcatcag agcagattgt actgagagtg caccatagc ggtgtgaaat 3960
accgcacaga tgcgtaagga gaaaataccg catcaggcga aattgtaaac gttaatat 4020
tgttaaaatt cgcgttaaat atttgttaaa tcagctcatt ttttaaccaa taggccgaaa 4080
tcggcaaaat cccttataaa tcaaaagaat agaccgagat aggggtgagt gttgttccag 4140
tttgaacaa gagtccacta ttaaagaacg tggactccaa cgtcaaagg cgaaaaaccg 4200
tctatcaggg cgatggccca ctacgtgaac catcacccaa atcaagttt ttgcggtcga 4260
ggtgcccgtaa agctctaaat cggaaacccta aaggagccc ccgatttaga gcttgacggg 4320
gaaagccggc gaacgtggcg agaaaggagc ggaagaaagc gaaaggagc ggcgtaggg 4380
cgctggcaag tgtagcgggt acgctgcgcg taaccaccac acccgccgcg cttaatgcgc 4440
cgctacaggg cgcgtccatt cgccattcag gctgcgcaac tgttggaag ggcgatcgg 4500
gcgggcctct tcgctattac gccagctggc gaaaggggga tgtgctgaa ggcgattaag 4560
ttgggtaacg ccagggtttt ccagtcacg acgttgtaaa acgacggcca gtgaattgta 4620
atacgactca ctataggggc aattcaaaaa acccctcaag acccgtttag aggcccaag 4680
gggttatgct agtgaattct gcagggtacc cggggatcct ctagagatcc ctcgacctcg 4740
agatccattg tgctgg 4756

```

&lt;210&gt; 4

&lt;211&gt; 4643

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGX52

&lt;400&gt; 4

```

gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaaattg taaacgttaa tattttgtta aaattcgcgt taaatatattg ttaaatacagc 120
tcatttttta accaataggc cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggt tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aaggcgaaaa aaccgtctat cagggcgatg gccactacg tgaaccatca 300
cccaaatcaa gttttttgcg gtcgaggtgc cgtaaagctc taaatcgga ccctaaagg 360
agccccgat ttagagcttg acggggaaa cggcgaaacg tggcgagaaa ggaagggaag 420
aaagcgaag gagcgggccc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacaccg ccgcgcttaa tgcgcgcta cagggcgctt ccattcgcca ttcaggctgc 540
gcaactgttg ggaaggcgga tccgtgcggg cctcttcgct attacgccag ctggcgaaaag 600
gggatgtgct tgcaaggcga ttaagtggg taacgccagg gttttcccag tcacgacgtt 660
gtaaacgac ggccagtga ttgtaatac actcactata gggcgaattc aaaaaaccc 720
tcaagaccg tttagaggcc ccaagggtt atgctagtga attctgcagg gtaccgggg 780
atcctctaga gatccctcga cctcgagatc cattgtgctg gcagccgatc tccgtcttgt 840
gaagatctac tccaccacca tccgtatcga tcagtccatc ctaccggag aatctgtgtc 900
tgttatcaag cacaccgact ctgtgccaga tccacgcgct gttaaccagg acaagaagaa 960
ttgtctgttc tcgggaacca atgtcgcatc tggaaaggct cgtggaatcg tcttcggaac 1020
cggattgacc actgaaatcg gaaagatccg taccgaaatg gctgagaccg agaatgagaa 1080
gacaccactt caacagaagt tggacgaatt cggagagcaa ctttccaagg ttatctctgt 1140
tatttgcgtt gctgtttggg ctatcaacat tggacatttc aacgatccag ctacaggttg 1200
atcatgggtt aaggagcaa tctactact caaaatcgcc gttgctcttg ccgtcgctgc 1260
tattccagaa ggacttccag ctgtcatcac cacgtgcctt gccctcgga ctcgccgtat 1320
ggccaagaag aacgctattg taagatccct tccatccgtc gaaactcttg gatgcacatc 1380
tggtatctgc tctgacaaga ctggaactct caccaccaac cagatgtctg tgtcaaagat 1440

```

gttcacgcgt	ggacaagcct	ctggagacaa	catcaacttc	accgagttcg	ccatctccgg	1500
atccacctac	gagccagtcg	gaaaggtttc	caccaatgga	cgtgaaatca	acccagctgc	1560
tggagaattc	gaatcactca	ccgagttggc	catgatctgc	gctatgtgca	atgattcatc	1620
tgttgattac	aatgagacca	agaagatcta	cgagaaagtc	ggagaagcca	ctgaaactgc	1680
tcttatcggt	cttgctgaga	agatgaatgt	tttcggaacc	tcgaaagccg	gactttcacc	1740
aaaggagctc	ggaggagttt	gcaaccgtgt	catccaacaa	aaatggaaga	aggagttcac	1800
actcgagttc	tcccgtgac	gtaaatccat	gtccgcctac	tgcttcccag	cttcgaggag	1860
atctggagcc	aagatgttcg	tgaaggagc	cccagaagga	gttctcggaa	gatgcaccca	1920
cgtcagagtt	aacggacaaa	aggttccact	cacctctgcc	atgactcaga	agattgttga	1980
ccaatgcgtg	caatacggaa	ccggaagaga	tacccttcgt	tgtcttgccc	tcggccagca	2040
caatggatct	cgagggatct	tccataccta	ccagttctgc	gcctgcaggt	cgcgcccgcg	2100
actctctaga	cgcgtaagct	tactagcata	accccttggg	gcctctaaac	gggtcttgag	2160
gggttttttg	agcttctcgc	cctatagtga	gtcgtattac	agcttgagta	ttctatagt	2220
tcacctaaat	agcttggcgt	aatcatggtc	atagctgttt	cctgtgtgaa	attgttatcc	2280
gtcacacaatt	ccacacaaca	tacgagccgg	aagcataaag	tgtaaagcct	ggggtgccta	2340
atgagtga	taactcacat	taattgcgtt	gcgctcactg	cccgccttcc	agtcgggaaa	2400
cctgtcgtgc	cagctgcatt	aatgaatcgg	ccaacgcgcg	gggagaggcg	gtttgcgtat	2460
tgggcgctct	tccgcttcct	cgctcactga	ctcgtcgcgc	tcggtcgttc	ggctgcggcg	2520
agcggatca	gctcactcaa	aggcggtaat	acggttatcc	acagaatcag	gggataacgc	2580
aggaaagaac	atgtgagca	aaggccagca	aaaggccagg	aaccgtaaaa	aggccgcgtt	2640
gctggcggtt	ttcgataggc	tccgcccccc	tgacgagcat	cacaaaaatc	gacgctcaag	2700
tcagaggtgg	cgaaacccga	caggactata	aagataccag	gcgtttcccc	ctggaagctc	2760
cctcgtgcgc	tctcctgttc	cgacctgccc	gcttaccgga	tacctgtccg	cctttctccc	2820
ttcgggaagc	gtggcgcttt	ctcatagctc	acgctgtagg	tatctcagtt	cggtgtaggt	2880
cgttcgctcc	aagctgggct	gtgtgcacga	accccccggt	cagcccgacc	gctgcgcctt	2940
atccggtaac	tatcgtcttg	agtccaaccc	ggtaagacac	gacttatcgc	cactggcagc	3000
agccactggt	aacaggatta	gcagagcgag	gtatgtaggc	ggtgctacag	agttcttgaa	3060
gtggtggcct	aactacggct	acactagaag	gacagtattt	ggtatctgcg	ctctgctgaa	3120
gccagttacc	ttcggaaaaa	gagttggtag	ctcttgatcc	ggcaaaaaaa	ccaccgctgg	3180
tagcgtgggt	ttttttgttt	gcaagcagca	gattacgcgc	agaaaaaaag	gatctcaaga	3240
agatcctttg	atcttttcta	cggggtctga	cgctcagttg	aacgaaaact	cacgttaagg	3300
gatttttggtc	atgagattat	caaaaaggat	cttcacctag	atccttttaa	attaaaaatg	3360
aagttttaaa	tcaatctaaa	gtatatatga	gtaaacttgg	tctgacagtt	accaatgctt	3420
aatcagtgag	gcacctatct	cagcgatctg	tctatttcgt	tcatccatag	ttgcctgact	3480
ccccgtcgtg	tagataacta	cgatacggga	gggcttacca	tctggcccca	gtgctgcaat	3540
gataccgcga	gacccacgct	caccggctcc	agatttatca	gcaataaacc	agccagccgg	3600
aagggccgag	cgcagaagtg	gtcctgcaac	tttatccgcc	tccatccagt	ctattaattg	3660
ttgccgggaa	gctagagtaa	gtagttcgcc	agttaatagt	ttgcgcaacg	ttggtggcat	3720
tgctacaggc	atcgtgggtg	cacgctcgtc	gtttggtatg	gcttcattca	gctccggttc	3780
ccaacgatca	aggcgagtta	catgatcccc	catgttctgc	aaaaaagcgg	ttagctcctt	3840
cggctcctcg	atcgttgtca	gaagtaagtt	ggcgcagtg	ttatcactca	tggttatggc	3900
agcactgcat	aattctctta	ctgtcatgcc	atccgtaaga	tgcttttctg	tgactggtga	3960
gtactcaacc	aagtcattct	gagaataccg	cgcccgcgca	ccgagttgct	cttgcccggc	4020
gtcaatacgg	gataatagt	tatgacatag	cagaacttta	aaagtgtca	tcattggaaa	4080
acgttcttcg	ggcgaaaaac	tctcaaggat	cttaccgctg	ttgagatcca	gttcgatgta	4140
acccactcgt	gcacccaact	gatcttcagc	atcttttact	ttcaccagcg	tttctgggtg	4200
agcaaaaaaca	ggaaggcaaa	atgccgcaaa	aaagggaata	agggcgacac	ggaaatggtg	4260
aatactcata	ctcttccttt	ttcaatatta	ttgaagcatt	tatcagggtt	attgtctcat	4320
gagcggatac	atatttgaat	gtatttagaa	aaataaacia	ataggggttc	cgcgcacatt	4380
tccccgaaaa	gtgccacctg	acgtctaaga	aaccattatt	atcatgacat	taacctataa	4440
aaataggcgt	atcacgagcg	cctttcgtct	cgcgcggttc	ggtgatgacg	gtgaaaacct	4500
ctgacacatg	cagctcccg	agacggtcac	agcttctctg	taagcggtatg	ccgggagcag	4560
acaagcccgt	cagggcgcg	cagcgggtgt	tggcgggtgt	cggggctggc	ttactatg	4620
ggcatcagag	cagattgtac	tga				4643

&lt;210&gt; 5

&lt;211&gt; 4454

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGX104

&lt;400&gt; 5

```

gagtgaccca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaattg taaacgttaa tatTTTgtta aaattcgcgt taaatatttg ttaaatacagc 120
tcatttttta accaataggc cgaaatcggc aaaatccctt ataaatcaaa agaataagacc 180
gagatagggg tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aagggcgaaa aaccgtctat cagggcgatg gccactacg tgaacatca 300
cccaaataca gttttttgcg gtcgaggtgc cgtaaagctc taaatcggaa ccctaaaggg 360
agcccccgat ttagagcttg acggggaaa gggcgagaaa ggaagggag 420
aaagcgaaag gagcgggagc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacaccgg ccgcgcttaa tgcgccgcta cagggcgcgct ccattcgcca ttcaggctgc 540
gcaactgttg ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaaag 600
ggggaatgtg tgcaaggcga ttaagttggg taacgccagg gttttcccag tcacgacgtt 660
gtaaaacgac ggccagtga ttgtaatacg actcactata gggcgaattc aaaaaacccc 720
tcaagaccgg tttagaggcc ccaaggggtt atgctagtga attctgcagg gtaccggggg 780
atcctctaga gatccctcga cctcgagatc cattgtgctg gaccgtggta ctcttatgga 840
gctcggaaatc tcgccaatcg tcaattctgg acttatcatg caacttctcg ccggagccaa 900
gatcatcgaa gtcggagaca caccaaagga ccgtgctctt ttcaacggag ccagaaatg 960
taagccgaaa agtggtgtgt ttcaatctct aatttttgaa cttttcagtg ttcgggtatg 1020
tcatcactgt tggacaagct attgtctacg tcatgtccgg actctacgga gagccatcgg 1080
aaatcggagc tggaatctgt ctcttatcgc tcgtccaact cgttattgcc ggtctcatcg 1140
tctctcttct cgacgagctt ctccaaaagg gatattggtc cggatccgga atttctctct 1200
tcattggcac caacatctgt gaaaccattg tctggaaggc attctccccg gcaacaatga 1260
acaccggacg tggaaaccgag ttcgaaggag ccgtcattgc tcttttccat cttcttgcca 1320
ccgctccga caaggtccgt gcccttcgtg aggttttcta ccgtcaaaac cttccaaact 1380
tgatgaactt gatggctact ttctcgttt ttgcggtggg tatctacttc caaggattcc 1440
gtgtcgacct cccaatcaag tctgcccgt accgtggaca atacagcagc taccatca 1500
agctcttcta cacctccaac attccaatca tcttcaatc tgcctcgcgc tccaacctct 1560
acgttatctc tcaggtttgt tgcattctcg tagtaccgtt agatgtttat ctttctctag 1620
agggtaagtg tggccgagaa attttttgag ttcatctca agtctgatgg aaaatgttta 1680
tttttcagat gctcgccgga aggttcggag gaaacttctt catcaacctt ctcggtacct 1740
ggtccgataa caccggatac agaagctacc caactggagg actctgctac tatctttcac 1800
caccagagtc tcttgacac atcttgaag acccaatcca ctgcaccagc acaatggatc 1860
tcgagggatc ttccatacct accagtctcg cgctgcagg tcgcgccgc gactctctag 1920
acgcgtaagc ttactagcat aacccttgg ggctctaaa cgggtcttga ggggtttttt 1980
gagcttctcg ccctatagtg agtcgtatta cagcttgagt attctatagt gtcacataaa 2040
tagcttggcg taatcatggg catagctgtt tcctgtgtga aattgttatc cgctcacaat 2100
tccacacaac atacgagccg gaagcataaa gtgtaaagcc tggggtgcct aatgagttag 2160
ctaactcaca ttaattgcgt tgcgctcact gcccgctttc cagtcgggaa acctgtcgtg 2220
ccagctgcat taatgaatcg gccaacgcgc ggggagaggg ggtttgcgta ttgggcgctc 2280
ttccgcttcc tcgctcactg actcgtcgcg ctcggtcgtt cggctgcggc gagcgtatc 2340
agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg caggaaagaa 2400
catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggctt 2460
tttcgatagg ctccgcccc ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg 2520
gcgaaacccg acaggactat aaagatacca ggcgtttccc cctggaagct ccctcgtgcg 2580
ctctcctgtt ccgaccctgc cgttaccgg atacctgtcc gcctttctcc cttcggaag 2640
cgtggcgctt tctcatagct cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc 2700
caagctgggc tgtgtgcagc aacccccgt tcagcccgac cgctgcgcct tatccggtaa 2760
ctatcgtctt gagtccaacc cggtaagaca cgacttatcg ccactggcag cagccactgg 2820
taacaggatt agcagagcga ggtatgtagg cgggtctaca gagttcttga agtggtggcc 2880
taactacggc tacactagaa ggacagtatt tggatctgct gctctgctga agccagttac 2940
cttcggaaaa agagtggta gctcttgatc cggcaaaaa accaccgctg gtagcggtgg 3000
tttttttgtt tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag aagatcctt 3060
gatcttttct acggggtctg acgctcagtg gaacgaaaac tcacgttaag ggattttggt 3120

```



```

catgagatta tcaaaaagga tcttcaccta gatcctttta aattaaaaat gaagttttta 3180
atcaatctaa agtatatatg agtaaaacttg gtctgacagt taccaatgct taatcagtga 3240
ggcacctatc tcagcgatct gtctattttcg ttcattccata gttgcctgac tccccgtcgt 3300
gtagataact acgatacggg agggccttacc atctggcccc agtgctgcaa tgataccgcg 3360
agaccacgc tcaccggctc cagattttatc agcaataaac cagccagccg gaagggccga 3420
gcgcagaagt ggtcctgcaa ctttatccgc ctccatccag tctattaatt gttgccggga 3480
agctagagta agtagttcgc cagttaatag tttgcgcaac gttgttgga ttgctacagg 3540
catcgtgggt tcacgctcgt cgtttggtat ggcttcattc agctccggtt cccaacgatc 3600
aaggcgagtt acatgatccc ccatgttggtg caaaaaagcg gttagctcct tcggctcctcc 3660
gatcgttgtc agaagtaagt tggccgcagt gttatcactc atggttatgg cagcactgca 3720
taattctctt actgtcatgc catccgtaag atgcttttct gtgactggtg agtactcaac 3780
caagtcattc tgagaatacc gcgcccggcg accgagttgc tcttgcccg cgtaataacg 3840
ggataatagt gtatgacata gcagaacttt aaaagtgtc atcattggaa aacgttcttc 3900
ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc agttcgatgt aaccactcg 3960
tgcacccaac tgatcttcag catcttttac tttcaccagc gtttctgggt gagcaaaaac 4020
aggaaggcaa aatgccgcaa aaaagggaa aagggcgaca cgaaaatgtt gaatactcat 4080
actcttcctt tttcaatatt attgaagcat ttatcagggt tattgtctca tgagcggata 4140
catatttgaa tgtatttaga aaaataaaca aataggggtt ccgcgcacat ttccccgaaa 4200
agtgccacct gacgtctaag aaaccattat tatcatgaca ttaacctata aaaataggcg 4260
tatcacgagg cccttcgctc tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat 4320
gcagctcccg gacgggtca cagcttgtct gtaagcggat gccgggagca gacaagcccg 4380
tcagggcgcg tcagcgggtg ttggcgggtg tcggggctgg cttaactatg cggcatcaga 4440
gcagattgta ctga 4454

```

&lt;210&gt; 6

&lt;211&gt; 4701

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGZ18

&lt;400&gt; 6

```

accagcttt cttgtacaaa gtggtgatct ttccagcaca atggatctcg agggatcttc 60
catacctacc agttctgcgc ctgcagggtcg cggccgcgac tctctagacg cgtaagctta 120
ctagcataac cccttggggc ctctaaacgg gtcttgaggg gttttttgag cttctcgccc 180
tatagttagt cgtattacag cttgagtatt ctatagtgtc acctaaatag cttggcgtaa 240
tcatggtcat agctgtttcc tgtgtgaaat tgttatccgc tcacaattcc acacaacata 300
cgagccggaa gcataaagtg taaagccttg ggtgcctaag gactgagcta actcacatta 360
attgcgttgc gctcactgcc cgctttccag tcgggaaacc tgtcgtgcca cgtgcattaa 420
tgaatcggcc aacgcgcggg gagaggcggt ttgcgtattg ggcgctcttc cgcttcctcg 480
ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc tactcaaaag 540
gcggtataac gggtatccac agaatcaggg gataacgcag gaaagaacat gtgagcaaaa 600
ggccagcaaa aggcaggaa ccgtaaaaag gccgcgttgc tggcgttttt cgataggctc 660
cgccccctg acgagcatca caaaaatcga cgctcaagtc agaggtggcg aaaccgcaga 720
ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgctc tcctgttccg 780
accctgccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct 840
catagctcac gctgtaggta tctcagttcg gtgtagggtc ttcgctccaa gctgggctgt 900
gtgcacgaac cccccgttca gcccgaccgc tgcgccttat ccggtacta tcgtcttgag 960
tccaacccgg taagacacga cttatcgcca ctggcagcag ccactggtaa caggattagc 1020
agagcgaggt atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa ctacggctac 1080
actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga 1140
gttggttagt cttgatccgg caaacaacc accgctggta gcggtggttt ttttgtttgc 1200
aagcagcaga ttacgcgcag aaaaaagga tctcaagaag atcctttgat cttttctacg 1260
gggtctgacg ctcagtggaa cgaaaactca cgtttaaggga ttttggtcat gagattatca 1320
aaaaggatct tcacctagat ctttttaaat taaaaatgaa gtttttaaat aatctaaagt 1380
atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtgaggc acctatctca 1440
gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta gataactacg 1500

```

atacgggagg	gettaccatc	tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	1560
ccgggtccag	atztatcagc	aataaaccag	ccagccggaa	gggcccagcg	cagaagtggg	1620
cctgcaactt	tatccgcctc	catccagtct	attaattggt	gccgggaagc	tagagtaagt	1680
agttcgccag	ttaatagttt	gcgcaacgtt	gttggcattg	ctacaggcat	cgtggtgtca	1740
cgctcgtcgt	ttggtatggc	ttcattcagc	tccggttccc	aacgatcaag	gcgagttaca	1800
tgatcccca	tgttgtgcaa	aaaagcgggt	agctccttcg	gtcctccgat	cgttgtcaga	1860
agtaagtgg	ccgcagtgtt	atcactcatg	gttatggcag	cactgcataa	ttctcttact	1920
gtcatgccat	ccgtaagatg	cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	1980
gaataccgcg	cccggcgacc	gagttgctct	tgcccggcgt	caatacggga	taatagtgtg	2040
tgacatagca	gaactttaaa	agtgtctatc	attggaaaac	gttcttcggg	gcgaaaactc	2100
tcaaggatct	taccgctggt	gagatccagt	tcgatgtaac	ccactcgtgc	acccaactga	2160
tcttcagcat	cttttacttt	caccagcgtt	tctgggtgag	caaaaacagg	aaggcaaaat	2220
gccgcaaaaa	aggggaataag	ggcgacacgg	aaatgttgaa	tactcatact	cttccttttt	2280
caatattatt	gaagcattta	tcagggttat	tgtctcatga	gcggatacat	atttgaatgt	2340
atttagaaaa	ataaacaat	aggggttcog	cgacatttc	cccgaaggt	gccacctgac	2400
gtctaagaaa	ccattattat	catgacatta	acctataaaa	ataggcgtat	cacgaggccc	2460
tttcgtctcg	cgcggttcgg	tgatgacggg	gaaaacctct	gacacatgca	gctcccggag	2520
acggtcacag	cttgtctgta	agcggatgcc	gggagcagac	aagcccgtca	gggcgcgtca	2580
gcgggtgttg	gcgggtgtcg	gggctggctt	aactatgcgg	catcagagca	gattgtactg	2640
agagtgcacc	atatgcggtg	tgaaataccg	cacagatgcg	taaggagaaa	ataccgcata	2700
aggcgaaatt	gtaaacgtta	atattttgtt	aaaattcgcg	ttaaatattt	gttaaatacag	2760
ctcatttttt	aaccaatagg	ccgaaatcgg	caaaatccct	tataaatcaa	aagaatagac	2820
cgagataggg	ttgagtgttg	ttccagtttg	gaacaagagt	ccactattaa	agaacgtgga	2880
ctccaacgtc	aaagggcgaa	aaaccgtcta	tcagggcgat	ggcccactac	gtgaaccatc	2940
acccaaatca	agttttttgc	ggtcagagtg	ccgtaaagct	ctaaatcgga	accctaagag	3000
gagccccoga	tttagagctt	gacggggaaa	gccggcgaa	gtggcgagaa	aggaagggaa	3060
gaaagcgaaa	ggagcgggcg	ctagggcgct	ggcaagtgtg	gcggtcacgc	tgccgctaac	3120
caccacaccc	gccgcgctta	atgcgcgct	acagggcgcg	tccattcgcc	attcaggctg	3180
cgcaactgtt	gggaaggcg	atcgggtcgg	gcctcttcgc	tattacgcca	gctggcgaaa	3240
gggggatgtg	ctgcaaggcg	attaagtgtg	gtaacgccag	ggttttccca	gtcacgacgt	3300
tgtaaaacga	cggccagtg	attgtaatac	gactcactat	agggcggaat	caaaaaaccc	3360
ctcaagaccc	gttttagagg	cccaaggggt	tatgctagt	aattctgcag	ggtacccggg	3420
gatectctag	agatccctcg	acctcgagat	ccattgtgct	ggaaagcctt	tgaggggctg	3480
gcaagccacg	tttgggtggt	gcgaccatcc	tccaaaatca	acaagtttgt	acaaaaagc	3540
aggctatgcc	aagtacatgt	cgattgcgta	cgcgttcgta	atgttggtcg	tgattgtcgc	3600
taccagcagt	caaattgttc	tcgagagtcg	gtttttacat	tatcccttca	tcctgattac	3660
gacaattttc	agctgttctc	gctcctacat	ctctcttcat	tgtcacaatg	gtcggaatct	3720
tcttctttgc	tgcatgtctt	catccaaaag	aattcacgaa	tattatccat	ggtgtcgtat	3780
tcttctctcat	gattccatct	acatatgtgt	tcctcacttt	atattcgctc	atcaatctca	3840
acgttatcac	gtggggaaact	cgtgaagctg	tcgctaaggc	aacgggacaa	aagacgaaaa	3900
aagcgcttat	ggaacaattt	atagacagag	tgattgatat	tgtgaaaaag	ggattcagat	3960
taatcagttg	tcggggagaag	aaggaacatg	aagagagacg	agagaaaatg	gaaaagaaaa	4020
tgagagaaat	ggagctagcc	ttgagaagta	ttgaggttat	ctttaacttt	agaaatgtga	4080
aattaataat	ttatttttcag	agtgggtccg	acgtgaagaa	aattctcgat	gcaacagagg	4140
agaaggagaa	acgtgaagaa	gaaactcaaa	ctgcagattt	tccgattgaa	gagaacgtag	4200
agaagactca	aaaagagatt	cagaaggcaa	accgttatgt	gtggatgaca	agtcatagct	4260
tgaaagtttg	tgaacgagga	aaactgaaaa	gtgcggaaaa	ggttttctgg	aacgagctca	4320
tcaatgcata	tctgaaaccg	atcaagacga	cgccagctga	aatgaaagcc	gtcgccgaag	4380
gattggcttc	tctacgaaat	cagattgtct	tcactattct	tctcgttaat	tctcttcttg	4440
ctcttgccat	ctttttgatt	cagaaacaca	aaaatgtgct	cagcatcaag	ttctcgccaa	4500
tcagtaagca	atattacctt	tatggtcaat	tcaaaaaatt	tgtttttttt	ttctagaaaa	4560
cttccgatgg	acgaaaatga	atgagatgac	tggacaatac	gaggaaaccg	atgaaccatt	4620
aaaaatagat	ccacttgga	tgggaattgt	tgttttcctt	ctaattattc	tttttgttca	4680
aactctcgga	atgcttctcc	a				4701

&lt;210&gt; 7

&lt;211&gt; 25

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide primer C04H5.6F

<400> 7

tgctcagaga gtttctcaac gaacc

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer C04H5.6R

<400> 8

caatgtagt tgctaggacc acctg

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer K11D9.2bF

<400> 9

cagccgatct ccgtcttgtg

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer K11D9.2bR

<400> 10

ccgagggcaa gacaacgaag

20

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer Y57G11C.15F

<400> 11

accgtggtac tcttatggag ctcg

24

<210> 12

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Oligonucleotide  
primer Y57G11C.15R

<400> 12  
tgcagtggat tgggtcttcg 20

<210> 13  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Oligonucleotide  
primer T25G3.2F

<400> 13  
ggggacaagt ttgtacaaaa aagcaggcta tgccaagtac atgtcgattg cg 52

<210> 14  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Oligonucleotide  
primer T25G3.2R

<400> 14  
ggggaccact ttgtacaaga aagctggggtt ggagaagcat tccgagagtt tg 52

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
**WO 01/48183 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/10, 9/22, C07K 14/435, C12N 15/66, 15/70, 1/00

(74) Agent: BAYLISS, Geoffrey, Cyril; Boulton Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(21) International Application Number: PCT/EP00/13149

(22) International Filing Date:  
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9930691.2 24 December 1999 (24.12.1999) GB

(71) Applicant (for all designated States except US): DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
6 December 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/48183 A3

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/13149

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/10 C12N9/22 C07K14/435 C12N15/66 C12N15/70  
C12N1/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TIMMONS L ET AL: "Specific interference by ingested dsRNA" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 395, no. 6705, 29 October 1998 (1998-10-29), page 854 XP002103601 ISSN: 0028-0836 the whole document	1-4, 12-21, 23-25, 28-31, 34-39
A	FIRE A ET AL: "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> " NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 391, 19 February 1998 (1998-02-19), pages 806-811, XP002095876 ISSN: 0028-0836 cited in the application the whole document	1-4



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

5 July 2001

Date of mailing of the international search report

20/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/13149

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHARP PHILLIP A: "RNAi and double-strand RNA." GENES & DEVELOPMENT, vol. 13, no. 2, 15 January 1999 (1999-01-15), pages 139-141, XP002171268 ISSN: 0890-9369 the whole document ---	1-4
A	RAY C ET AL: "GUT-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF A CAENORHABDITIS ELEGANS CYSTEINE PROTEASE GENE" MOLECULAR AND BIOCHEMICAL PARASITOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 51, 1992, pages 239-249, XP000572340 ISSN: 0166-6851 abstract ---	2-4,8
A	RAND J B ET AL: "GENETIC PHARMACOLOGY: INTERACTIONS BETWEEN DRUGS AND GENE PRODUCTS IN CAENORHABDITIS ELEGANS" METHODS IN CELL BIOLOGY,LONDON,GB, vol. 84, 1995, pages 187-204, XP000956211 page 190, paragraph 1 -page 194, paragraph 4 ---	1-4,8
A	AVERY LEON ET AL: "The Caenorhabditis elegans unc-31 gene affects multiple nervous system-controlled functions." GENETICS, vol. 134, no. 2, 1993, pages 455-464, XP001011453 ISSN: 0016-6731 the whole document ---	2-4,8
A	TAGESSON C ET AL: "INFLUENCE OF SURFACE-ACTIVE FOOD ADDITIVES ON THE INTEGRITY AND PERMEABILITY OF RAT INTESTINAL MUCOSA" FOOD AND CHEMICAL TOXICOLOGY, vol. 22, no. 11, 1984, pages 861-864, XP001009621 ISSN: 0278-6915 the whole document --- -/--	8

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/13149

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	<p>LYON CHRISTOPHER J ET AL: "The C. elegans apoptotic nuclease NUC-1 is related in sequence and activity to mammalian DNase II."</p> <p>GENE (AMSTERDAM), vol. 252, no. 1-2, 11 July 2000 (2000-07-11), pages 147-154, XP001009494 ISSN: 0378-1119 abstract; figure 3 page 151, right-hand column, paragraph 2 -page 153, right-hand column, paragraph 2</p>	6,7
P,X	<p>WO 00 01846 A (MORTIER KATHERINE ;DEVGEN NV (BE); BOGAERT THIERRY (BE); PLAETINCK) 13 January 2000 (2000-01-13) cited in the application</p> <p>page 8, line 9 -page 10, line 22 page 12, line 14 -page 23, line 2 figures 5,9; examples 1-4</p>	1-4, 12-21, 23-25, 28-31, 34-39
P,X	<p>WO 00 63425 A (FEICHTINGER RICHARD ;BEGHYN MYRIAM (BE); DEVGEN NV (BE); BOGAERT T) 26 October 2000 (2000-10-26) abstract page 2, line 14-30 page 6, line 18-33 page 7, line 12 -page 9, line 28 page 12, line 20 -page 13, line 25; example 3</p>	2-5,8,9, 29-33
T	<p>TIMMONS LISA ET AL: "Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans."</p> <p>GENE (AMSTERDAM), vol. 263, no. 1-2, 2001, pages 103-112, XP001009512 ISSN: 0378-1119 the whole document</p>	1-4, 12-21, 23-26, 28-31, 34-39



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/13149

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0001846 A	13-01-2000	AU 4907999 A	24-01-2000
		EP 1093526 A	25-04-2001
		GB 2349885 A	15-11-2000
		NO 20010019 A	05-03-2001
WO 0063425 A	26-10-2000	AU 3984600 A	02-11-2000
		GB 2351152 A	20-12-2000

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**